Transfer of myxovirus-protein-A mRNA assay for interferon-β bioactivity measurement in multiple sclerosis patients to routine laboratory practice. A 4-year experience

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 9, 2010, Pages 1235-1238

  Zanotti, Cinzia ^a   Ghidini, Claudia ^a   Lamorgese, Cinzia ^a   Caimi, Luigi ^a   Capra, Ruggero ^b   Imberti, Luisa ^a  

^a Laboratory of Biotechnology   (Italy)

^b Multiple Sclerosis Center   (Italy)

Author keywords

interferon ; multiple sclerosis; myxovirus protein A; routine laboratory practice

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; MESSENGER RNA; VIRUS PROTEIN;

ADULT; ANTIBODY DETECTION; ARTICLE; ASSAY; CLINICAL PRACTICE; DRUG ACTIVITY; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ORTHOMYXOVIRUS; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING; VALIDATION STUDY;

ADULT; FEMALE; HUMANS; INTERFERON-BETA; LABORATORIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; ORTHOMYXOVIRIDAE; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RNA, MESSENGER; STAPHYLOCOCCAL PROTEIN A; TIME FACTORS; TREATMENT OUTCOME; VIRAL PROTEINS;

ORTHOMYXOVIRIDAE;

EID: 77957311825     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.263     Document Type: Article

References (9)

1. Goodin DS, Frohman EM, Hurwitz B, O'Connor PW, Oger JJ, Reder AT, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007;68:977-84. (Pubitemid 46569129)
2. Pachner A, Narayan K, Price N, Hurd M, Dail D. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 2003;7:17-25. (Pubitemid 37339029)
3. Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Capobianco M, et al. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler 2006;12:47-57. (Pubitemid 43169237)
4. Van der Voort LF, Kok A, Visser A, Oudejans CB, Caldano M, Gilli F, et al. Interferon-b bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice. Mult Scler 2009;15:212-8.
5. Capra R, Sottini A, Cordioli C, Serana F, Chiarini M, Caimi L, et al. IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays. J Neuroimmunol 2007;189:102-10. (Pubitemid 47385828)
6. McKay F, Schibeci S, Heard R, Stewart G, Booth D. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort. J Immunol Methods 2006;310:20-9. (Pubitemid 43375972)
7. Pachner AR, Dail D, Pak E, Narayan K. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J Neuroimmunol 2005;166:180-8. (Pubitemid 41078773)
8. Bertolotto A, Sala A, Malucchi S, Marnetto F, Caldano M, Di Sapio A, et al. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry 2004;75:1294-9. (Pubitemid 39141336)
9. Bertolotto A, Gilli F, Sala A, Capobianco M, Malucchi S, Milano E, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003;60:634-9. (Pubitemid 36246082)